CDK6 overexpression resulted from microRNA‑320d downregulation promotes cell proliferation in diffuse large B‑cell lymphoma

Su,Hong; Chang,Jiang; Xu,Mengwei; Sun,Ruifang; Wang,Jinfen

doi:10.3892/or.2019.7144

CDK6 overexpression resulted from microRNA‑320d downregulation promotes cell proliferation in diffuse large B‑cell lymphoma

Authors:
- Hong Su
- Jiang Chang
- Mengwei Xu
- Ruifang Sun
- Jinfen Wang
View Affiliations

Affiliations: Department of Pathology, Shanxi Cancer Hospital, Taiyuan, Shanxi 030013, P.R. China, Department of Pathology, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China
Published online on: May 2, 2019 https://doi.org/10.3892/or.2019.7144
Pages: 321-327

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The molecular and clinical heterogeneity in diffuse large B‑cell lymphoma (DLBCL) has raised a need for the investigation of potential therapeutic biomarkers. MicroRNA‑320 (miR‑320) and CDK6 are both involved in the regulation of cell proliferation in various types of cancer. To investigate the clinical role of CDK6 in DLBCL, CDK6 expression was assessed using immunohistochemistry on formalin‑fixed, paraffin‑embedded sections. Furthermore, to investigate the relationship between CDK6 and miR‑320d, as well as their roles in cell proliferation, a series of experimentally functional validations was performed in DLBCL cell lines. Bioinformatics software and Dual‑Luciferase reporter assay were used to predict and validate the potential target of miR‑320d. In DLBCL cells transfected with miR‑320d lentiviral vector, CDK6 expression at the protein and mRNA levels was detected using western blotting and qRT‑PCR, respectively. Overexpression and small‑hairpin RNA knockdown of CDK6 were performed by lentiviral transduction. The results of these experiments revealed that CDK6 was overexpressed and predictive of poor prognosis in DLBCL patients. Moreover, CDK6 was revealed to be directly targeted by miR‑320d and either overexpression of miR‑320d or knockdown of CDK6 inhibited proliferation. In conclusion, CDK6 overexpression in DLBCL may result from miRNA‑320d downregulation and subsequent loss of inhibition of cell proliferation, suggesting that miRNA‑320d may be a potential therapeutic target for the treatment of DLBCL with high CDK6 expression.

View Figures

View References

1	Lossos IS: Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol. 23:6351–6357. 2005. View Article : Google Scholar : PubMed/NCBI
2	Abramson JS and Shipp MA: Advances in the biology and therapy of diffuse large B-cell lymphoma: Moving toward a molecularly targeted approach. Blood. 106:1164–1174. 2005. View Article : Google Scholar : PubMed/NCBI
3	Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
4	Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 346:1937–1947. 2002. View Article : Google Scholar : PubMed/NCBI
5	Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 103:275–282. 2004. View Article : Google Scholar : PubMed/NCBI
6	Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, et al: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010. View Article : Google Scholar : PubMed/NCBI
7	Behm-Ansmant I, Rehwinkel J and Izaurralde E: MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol. 71:523–530. 2006. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Filipowicz W: RNAi: The nuts and bolts of the RISC machine. Cell. 122:17–20. 2005. View Article : Google Scholar : PubMed/NCBI
10	White RE and Giffard RG: MicroRNA-320 induces neurite outgrowth by targeting ARPP-19. Neuroreport. 23:590–595. 2012. View Article : Google Scholar : PubMed/NCBI
11	Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ, Lee KH, Yeh SD, Hong TM and Chen YL: MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis. 34:530–538. 2013. View Article : Google Scholar : PubMed/NCBI
12	Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, Srinivasan R, Trimboli AJ, Martin CK, Li F, et al: Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol. 14:159–167. 2011. View Article : Google Scholar : PubMed/NCBI
13	Zhi F, Cao X, Xie X, Wang B, Dong W, Gu W, Ling Y, Wang R, Yang Y and Liu Y: Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. PLoS One. 8:e567182013. View Article : Google Scholar : PubMed/NCBI
14	Yan Q, Li W, Tang Q, Yao S, Lv Z, Feng N, Ma X, Bai Z, Zeng Y, Qin D, et al: Cellular microRNAs 498 and 320d regulate herpes simplex virus 1 induction of Kaposi's sarcoma-associated herpesvirus lytic replication by targeting RTA. PLoS One. 8:e558322013. View Article : Google Scholar : PubMed/NCBI
15	Zhu H, Jiang X, Zhou X, Dong X, Xie K, Yang C, Jiang H, Sun X and Lu J: Neuropilin-1 regulated by miR-320 contributes to the growth and metastasis of cholangiocarcinoma cells. Liver Int. 38:125–135. 2018. View Article : Google Scholar : PubMed/NCBI
16	Baba Y, Watanabe M, Murata A, Shigaki H, Miyake K, Ishimoto T, Iwatsuki M, Iwagami S, Yoshida N, Oki E, et al: LINE-1 hypomethylation, DNA copy number alterations, and CDK6 amplification in esophageal squamous cell carcinoma. Clin Cancer Res. 20:1114–1124. 2014. View Article : Google Scholar : PubMed/NCBI
17	van Dekken H, van Marion R, Vissers KJ, Hop WC, Dinjens WN, Tilsanus HW, Wink JC and van Duin M: Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels. Genes Chromosomes Cancer. 47:649–656. 2008. View Article : Google Scholar : PubMed/NCBI
18	Wang G, Zheng L, Yu Z, Liao G, Lu L, Xu R, Zhao Z and Chen G: Increased cyclin-dependent kinase 6 expression in bladder cancer. Oncol Lett. 4:43–46. 2012. View Article : Google Scholar : PubMed/NCBI
19	Tsai JW, Li CF, Kao YC, Wang JW, Fang FM, Wang YH, Wu WR, Wu LC, Hsing CH, Li SH, et al: Recurrent amplification at 7q21.2 targets CDK6 gene in primary myxofibrosarcomas and identifies CDK6 overexpression as an independent adverse prognosticator. Ann Surg Oncol. 19:2716–2725. 2012. View Article : Google Scholar : PubMed/NCBI
20	Whiteway SL, Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Foreman NK and Vibhakar R: Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells. J Neurooncol. 111:113–121. 2013. View Article : Google Scholar : PubMed/NCBI
21	Wu PY, Zhang XD, Zhu J, Guo XY and Wang JF: Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone. Hum Pathol. 45:1664–1673. 2014. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ and van den Berg A: BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 207:243–249. 2005. View Article : Google Scholar : PubMed/NCBI
24	Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood J, et al: MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer. 121:1156–1161. 2007. View Article : Google Scholar : PubMed/NCBI
25	He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, et al: A microRNA polycistron as a potential human oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
26	Roehle A, Hoefig KP, Repsilber D, Thorns C, Ziepert M, Wesche KO, Thiere M, Loeffler M, Klapper W, Pfreundschuh M, et al: MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol. 142:732–744. 2008. View Article : Google Scholar : PubMed/NCBI
27	Högfeldt T, Johnsson P, Grandér D, Bahnassy AA, Porwit A, Eid S, Österborg A, Zekri AR, Lundahl J, Khaled MH, et al: Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas. Leuk Lymphoma. 55:1158–1165. 2014. View Article : Google Scholar : PubMed/NCBI
28	Mazan-Mamczarz K, Zhao XF, Dai B, Steinhardt JJ, Peroutka RJ, Berk KL, Landon AL, Sadowska M, Zhang Y, Lehrmann E, et al: Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development. PLoS Genet. 10:e10041052014. View Article : Google Scholar : PubMed/NCBI
29	Geraldo MV, Yamashita AS and Kimura ET: MicroRNA miR-146b-5p regulates signal transduction of TGF-^β by repressing SMAD4 in thyroid cancer. Oncogene. 31:1910–1922. 2012. View Article : Google Scholar : PubMed/NCBI
30	van der Linden MH, Willekes M, van Roon E, Seslija L, Schneider P, Pieters R and Stam RW: MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL. Cell Cycle. 13:834–844. 2014. View Article : Google Scholar : PubMed/NCBI
31	Lucas JJ, Domenico J and Gelfand EW: Cyclin-dependent kinase 6 inhibits proliferation of human mammary epithelial cells. Mol Cancer Res. 2:105–114. 2004.PubMed/NCBI
32	Wang Y, Li Y, Sun J, Wang Q, Sun C, Yan Y, Yu L, Cheng D, An T, Shi C, et al: Tumor-suppressive effects of miR-29c on gliomas. Neuroreport. 24:637–645. 2013. View Article : Google Scholar : PubMed/NCBI
33	Zhang Z, Huang L, Yu Z, Chen X, Yang D, Zhan P, Dai M, Huang S, Han Z and Cao K: Let-7a functions as a tumor suppressor in Ewing's sarcoma cell lines partly by targeting cyclin-dependent kinase 6. DNA Cell Biol. 33:136–147. 2014. View Article : Google Scholar : PubMed/NCBI
34	Classon M and Harlow E: The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2:910–917. 2002. View Article : Google Scholar : PubMed/NCBI
35	Bustos MA, Ono S, Marzese DM, Oyama T, Iida Y, Cheung G, Nelson N, Hsu SC, Yu Q and Hoon DSB: MiR-200a regulates CDK4/6 inhibitor effect by targeting CDK6 in metastatic melanoma. J Invest Dermatol. 137:1955–1964. 2017. View Article : Google Scholar : PubMed/NCBI